How treatment choices influence the onset and outcomes of uveitis ın juvenile idiopathic arthritis: a retrospective cohort study [0.03%]
治疗选择如何影响幼年特发性关节炎虹膜炎的发病和结局：回顾性队列研究
Sinan Işık,Selen Duygu Arık,Özlem Akgün et al.
Sinan Işık et al.
Objectives: Uveitis is a prevalent complication of juvenile idiopathic arthritis (JIA), leading to ocular morbidity. This study aimed to evaluate uveitis frequency in JIA patients on biologics and explore the impact of bi...
Treatment sequences in moderate-to-severe psoriasis: a hospital-based retrospective analysis [0.03%]
中重度银屑病治疗模式的医院回溯分析
Angela Boccia,Valentina Giunchi,Luca Girau et al.
Angela Boccia et al.
Background: For moderate-to-severe psoriasis, clinical guidelines recommend biologic treatments after failure of at least one traditional systemic therapy. Biologics target different pathways, but a common challenge is lo...
Matti Aapro,Peyman Hadji,Daniele Santini et al.
Matti Aapro et al.
Introduction: Osteoporosis is a significant public health issue due to its associated morbidity, mortality, and economic burden. Despite available effective treatments, a treatment gap persists, characterized by delayed d...
Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized, double-blind, phase 3 STELLAR-2 study [0.03%]
USTEKINUMAB 生物仿制药Bmab 1200 治疗中重度斑块状银屑病疗效和安全性：随机双盲III期STELLAR-2研究的28周结果
Jacek C Szepietowski,Adam Reich,Steven R Feldman et al.
Jacek C Szepietowski et al.
Background: STELLAR-2 assessed the equivalent efficacy of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in patients with moderate-to-severe chronic plaque psoriasis. Safety, immunogenicity, and pharm...
Advanced therapies targeting IL-23: clinical outcomes in ulcerative colitis [0.03%]
靶向IL-23的先进疗法：溃疡性结肠炎的临床疗效
Silvia Salvatori,Irene Marafini,Antonio Fonsi et al.
Silvia Salvatori et al.
Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by a relapsing-remitting colonic inflammation. Despite advances in understanding UC pathogenesis, a definitive cure remains elusi...
A randomized, double blind, parallel design, repeat dose, 2-arm, multicenter study comparing the efficacy, safety, immunogenicity, and pharmacokinetic profiles of a denosumab biosimilar, AVT03, in postmenopausal women with osteoporosis [0.03%]
一项在绝经后女性骨质疏松患者中，评价AVT03与安进尼尔雌マ的疗效、安全性和免疫原性且具有药代动力学特性的随机、双盲、平行分组、多中心的重复给药II期临床试验
Mamuka Lortkipanidze,Tobie de Villiers,Grzegorz Kania et al.
Mamuka Lortkipanidze et al.
Background: To demonstrate comparative efficacy of AVT03, a proposed denosumab biosimilar, versus reference product (RP) in postmenopausal women with osteoporosis. ...
Progress in the use of type I interferon blockade in systemic lupus erythematosus [0.03%]
I型干扰素阻断在系统性红斑狼疮治疗中的进展
Iolanda Miceli,Eric F Morand,Sarah A Jones
Iolanda Miceli
Introduction: The successful clinical trials of the type I interferon (IFN) receptor monoclonal antibody, anifrolumab, have proven the benefit of IFN blockade in systemic lupus erythematosus (SLE), and paved the way for n...
Clinical use of biologics in juvenile idiopathic arthritis: lessons learned from real-world studies [0.03%]
生物制剂治疗青少年特发性关节炎的临床应用：真实世界研究的经验教训
Sıla Atamyıldız Uçar,Betül Sözeri
Sıla Atamyıldız Uçar
Introduction: This review aims to summarize real-world evidence on the use of biologic therapies in juvenile idiopathic arthritis (JIA), including systemic and non-systemic subtypes, and to explore treatment strategies. ...
Predicting and overcoming poor patient responses to sublingual immunotherapy for allergic diseases [0.03%]
预测并克服过敏性疾病舌下免疫治疗不良患者反应
Maria Angela Tosca,Chiara Ferrecchi,Talia D&#x;ambrosio et al.
Maria Angela Tosca et al.
Introduction: Allergen immunotherapy (AIT) is the only disease-modifying treatment for allergic rhinitis and asthma. Sublingual immunotherapy (SLIT) is commonly used in clinical practice. Although its effectiveness has be...